Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance follows positive phase 2 data on the company’s tri-specific antibody tilrekimig.
Piotr Kowalski/Shutterstock.com
Trial results showed that the once-a-month inhibitor achieved a placebo-adjusted high of 51.9% in the middle-dose group. It compares to a high of 36% at 16 weeks for Regeneron’s Dupixent. The investigational drug also met its primary endpoint in the Phase 2 study for adults with atopic dermatitis, a skin disease that causes itching.
The trial results suggest a potentially higher competitive profile, with greater efficacy than the current treatment option from Sanofi and Regeneron. The positive results strengthen the company’s positioning in the immunology and inflammation sectors. In addition, it should provide Pfizer with a catalyst as it continues to rebuild momentum across its pipeline.
Pfizer Inc. (NYSE:PFE) is a leading global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines and vaccines to treat and prevent diseases. Focused on oncology, inflammation, immunology, and vaccines, Pfizer offers over 150 products worldwide, including major COVID-19 vaccines and treatments.
While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: finance.yahoo.com
